Cargando…
Development of a novel chemoenzymatic route to enantiomerically enriched β-adrenolytic agents. A case study toward propranolol, alprenolol, pindolol, carazolol, moprolol, and metoprolol
Efficient chemoenzymatic routes toward the synthesis of both enantiomers of adrenergic β-blockers were accomplished by identifying a central chiral building block, which was first prepared using lipase-catalyzed kinetic resolution (KR, Amano PS-IM) as the asymmetric step at a five gram-scale (209 mM...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364081/ https://www.ncbi.nlm.nih.gov/pubmed/36043081 http://dx.doi.org/10.1039/d2ra04302e |
_version_ | 1784765073720344576 |
---|---|
author | Borowiecki, Paweł Zdun, Beata Popow, Natalia Wiklińska, Magdalena Reiter, Tamara Kroutil, Wolfgang |
author_facet | Borowiecki, Paweł Zdun, Beata Popow, Natalia Wiklińska, Magdalena Reiter, Tamara Kroutil, Wolfgang |
author_sort | Borowiecki, Paweł |
collection | PubMed |
description | Efficient chemoenzymatic routes toward the synthesis of both enantiomers of adrenergic β-blockers were accomplished by identifying a central chiral building block, which was first prepared using lipase-catalyzed kinetic resolution (KR, Amano PS-IM) as the asymmetric step at a five gram-scale (209 mM conc.). The enantiopure (R)-chlorohydrin (>99% ee) subsequently obtained was used for the synthesis of a series of model (R)-(+)-β-blockers (i.e., propranolol, alprenolol, pindolol, carazolol, moprolol, and metoprolol), which were produced with enantiomeric excess in the range of 96–99.9%. The pharmaceutically relevant (S)-counterpart, taking propranolol as a model, was synthesized in excellent enantiomeric purity (99% ee) via acetolysis of the respective enantiomerically pure (R)-mesylate by using cesium acetate and a catalytic amount of 18-Crown-6, followed by acidic hydrolysis of the formed (S)-acetate. Alternatively, asymmetric reduction of a prochiral ketone, namely 2-(3-chloro-2-oxopropyl)-1H-isoindole-1,3(2H)-dione, was performed using lyophilized E. coli cells harboring overexpressed recombinant alcohol dehydrogenase from Lactobacillus kefir (E. coli/Lk-ADH-Lica) giving the corresponding chlorohydrin with >99% ee. Setting the stereocenter early in the synthesis and performing a 4-step reaction sequence in a ‘one-pot two-step’ procedure allowed the design of a ‘step-economic’ route with a potential dramatic improvement in process efficiency. The synthetic method can serve for the preparation of a broad scope of enantiomerically enriched β-blockers, the chemical structures of which rely on the common α-hydroxy-N-isopropylamine moiety, and in this sense, might be industrially attractive. |
format | Online Article Text |
id | pubmed-9364081 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Royal Society of Chemistry |
record_format | MEDLINE/PubMed |
spelling | pubmed-93640812022-08-29 Development of a novel chemoenzymatic route to enantiomerically enriched β-adrenolytic agents. A case study toward propranolol, alprenolol, pindolol, carazolol, moprolol, and metoprolol Borowiecki, Paweł Zdun, Beata Popow, Natalia Wiklińska, Magdalena Reiter, Tamara Kroutil, Wolfgang RSC Adv Chemistry Efficient chemoenzymatic routes toward the synthesis of both enantiomers of adrenergic β-blockers were accomplished by identifying a central chiral building block, which was first prepared using lipase-catalyzed kinetic resolution (KR, Amano PS-IM) as the asymmetric step at a five gram-scale (209 mM conc.). The enantiopure (R)-chlorohydrin (>99% ee) subsequently obtained was used for the synthesis of a series of model (R)-(+)-β-blockers (i.e., propranolol, alprenolol, pindolol, carazolol, moprolol, and metoprolol), which were produced with enantiomeric excess in the range of 96–99.9%. The pharmaceutically relevant (S)-counterpart, taking propranolol as a model, was synthesized in excellent enantiomeric purity (99% ee) via acetolysis of the respective enantiomerically pure (R)-mesylate by using cesium acetate and a catalytic amount of 18-Crown-6, followed by acidic hydrolysis of the formed (S)-acetate. Alternatively, asymmetric reduction of a prochiral ketone, namely 2-(3-chloro-2-oxopropyl)-1H-isoindole-1,3(2H)-dione, was performed using lyophilized E. coli cells harboring overexpressed recombinant alcohol dehydrogenase from Lactobacillus kefir (E. coli/Lk-ADH-Lica) giving the corresponding chlorohydrin with >99% ee. Setting the stereocenter early in the synthesis and performing a 4-step reaction sequence in a ‘one-pot two-step’ procedure allowed the design of a ‘step-economic’ route with a potential dramatic improvement in process efficiency. The synthetic method can serve for the preparation of a broad scope of enantiomerically enriched β-blockers, the chemical structures of which rely on the common α-hydroxy-N-isopropylamine moiety, and in this sense, might be industrially attractive. The Royal Society of Chemistry 2022-08-10 /pmc/articles/PMC9364081/ /pubmed/36043081 http://dx.doi.org/10.1039/d2ra04302e Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | Chemistry Borowiecki, Paweł Zdun, Beata Popow, Natalia Wiklińska, Magdalena Reiter, Tamara Kroutil, Wolfgang Development of a novel chemoenzymatic route to enantiomerically enriched β-adrenolytic agents. A case study toward propranolol, alprenolol, pindolol, carazolol, moprolol, and metoprolol |
title | Development of a novel chemoenzymatic route to enantiomerically enriched β-adrenolytic agents. A case study toward propranolol, alprenolol, pindolol, carazolol, moprolol, and metoprolol |
title_full | Development of a novel chemoenzymatic route to enantiomerically enriched β-adrenolytic agents. A case study toward propranolol, alprenolol, pindolol, carazolol, moprolol, and metoprolol |
title_fullStr | Development of a novel chemoenzymatic route to enantiomerically enriched β-adrenolytic agents. A case study toward propranolol, alprenolol, pindolol, carazolol, moprolol, and metoprolol |
title_full_unstemmed | Development of a novel chemoenzymatic route to enantiomerically enriched β-adrenolytic agents. A case study toward propranolol, alprenolol, pindolol, carazolol, moprolol, and metoprolol |
title_short | Development of a novel chemoenzymatic route to enantiomerically enriched β-adrenolytic agents. A case study toward propranolol, alprenolol, pindolol, carazolol, moprolol, and metoprolol |
title_sort | development of a novel chemoenzymatic route to enantiomerically enriched β-adrenolytic agents. a case study toward propranolol, alprenolol, pindolol, carazolol, moprolol, and metoprolol |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364081/ https://www.ncbi.nlm.nih.gov/pubmed/36043081 http://dx.doi.org/10.1039/d2ra04302e |
work_keys_str_mv | AT borowieckipaweł developmentofanovelchemoenzymaticroutetoenantiomericallyenrichedbadrenolyticagentsacasestudytowardpropranololalprenololpindololcarazololmoprololandmetoprolol AT zdunbeata developmentofanovelchemoenzymaticroutetoenantiomericallyenrichedbadrenolyticagentsacasestudytowardpropranololalprenololpindololcarazololmoprololandmetoprolol AT popownatalia developmentofanovelchemoenzymaticroutetoenantiomericallyenrichedbadrenolyticagentsacasestudytowardpropranololalprenololpindololcarazololmoprololandmetoprolol AT wiklinskamagdalena developmentofanovelchemoenzymaticroutetoenantiomericallyenrichedbadrenolyticagentsacasestudytowardpropranololalprenololpindololcarazololmoprololandmetoprolol AT reitertamara developmentofanovelchemoenzymaticroutetoenantiomericallyenrichedbadrenolyticagentsacasestudytowardpropranololalprenololpindololcarazololmoprololandmetoprolol AT kroutilwolfgang developmentofanovelchemoenzymaticroutetoenantiomericallyenrichedbadrenolyticagentsacasestudytowardpropranololalprenololpindololcarazololmoprololandmetoprolol |